COLLABORATION AND LICENSE AGREEMENT BY AND AMONG ARGENX BVBA AND ARGENX SE (SOLELY FOR PURPOSES OF SECTIONS 16.2 AND 16.3) AND CILAG GMBH INTERNATIONALCollaboration and License Agreement • March 26th, 2019 • Argenx Se • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (the “Agreement”) is made and effective as of December 2, 2018 (the “Execution Date”) by and between argenx BVBA, a Belgian company (“argenx”) and, solely for purposes of Sections 16.2 and 16.3, argenx SE, a Societas Europaea (“Parent”), on the one hand, and Cilag GmbH International, a Swiss company (“Janssen”), on the other hand.
INVESTMENT AGREEMENT Between argenx SE and Johnson & Johnson Innovation – JJDC, Inc. (the Agreement)Investment Agreement • March 26th, 2019 • Argenx Se • Biological products, (no disgnostic substances)
Admission means the admission to trading of the Investment Securities on the regulated market Euronext Brussels organised by Euronext Brussels NV/SA;
